CEO BOARD UPDATE

Seth Berkley, CEO

Board meeting
24–25 June 2020
Key developments in global landscape
COVID-19: an unprecedented global challenge

January–June 2020: spread to 214 countries and territories

Credit: COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU): https://coronavirus.jhu.edu/map.html

Cumulative confirmed cases
(as of 17 June 2020)
COVID-19: devastating global impact

• **WHO data on health impact**
  • Global deaths: >440,000; global cases: >8 million
  • Immunisation programmes and other essential health services disrupted

• **OECD Economic Outlook, June 2020: most severe economic recession in nearly 100 yrs**
  • Two scenarios possible:
    • If 2nd wave avoided: economic activity falls 6% in 2020; unemployment climbs to >9%
    • If 2nd wave hits in 2020: economic output plummets >7% this year; unemployment nearly doubles to 10%

• **Disproportionate impact on vulnerable communities**
  • OCHA: world’s most fragile places will see disease peak in 3–6 months
  • World Bank: first net rise in global poverty in >20 yrs

Board meeting
24–25 June 2020
Gavi replenishment and the Global Vaccine Summit 2020
Gavi@20: World Economic Forum, Davos

January 2000

January 2020

Board meeting
24–25 June 2020
Global Vaccine Summit 2020: 4 June 2020

Global solidarity, recognition of Gavi’s mission of equitable access

- 42 heads of state, including all 7 of G7
- 52 countries represented, including heads of state and representatives of 19 of the G20
- 14 Gavi-supported countries participated
- >180,000 people watched online

Board meeting
24–25 June 2020
Pledges and commitments

- Foundations laid at World Economic Forum and EC Global Coronavirus Response Pledging Conference

- Additional US$ 8.8 billion raised for Gavi’s next strategic period (2021–2025), for a total of US$ 10.5 billion available for Gavi 5.0

- Close to US$ 1 billion included for Gavi through IFFIm

- Private sector partners pledged more than US$ 70 million to strengthen Gavi programmes

- More than US$ 0.5 billion available to jumpstart COVID-19 vaccine purchase (Gavi COVAX AMC)
  - MOU for 300 million doses of first COVID-19 vaccine for COVAX Facility announced
Manufacturers commit to supply HPV vaccine for 84 million girls

- Five manufacturers pledged to ramp up human papillomavirus (HPV) vaccine supply for Gavi-supported countries
- New supply to protect 84 million girls, instead of 50 million girls, from 2021–2025
- An estimated 1.4 million future deaths from cervical cancer will be prevented
COVID-19 response: Gavi’s role
Gavi-eligible countries account for ~11% of global COVID-19 cases*

COVID-19 cases by Gavi-eligible country

- 70 (out of 73) Gavi-eligible countries have reported cases
- 824,259 confirmed cases
- 20,641 deaths

*World Health Organization data as of 16 June 2020

Source:
Prioritising immunisation, an essential health service, during COVID-19 pandemic

Impact on Gavi-supported countries

- 66% of introductions/campaigns delayed or at risk
- Uptake of routine services reduced
- Global supply disruptions
- Increase in vaccine hesitancy and misinformation
- Outbreaks of vaccine preventable diseases

Gavi’s immediate and interim programmatic response

- Up to US$ 200 million available for immediate response and preparedness; flexibilities in policies and processes
- Maintaining and restoring immunisation
- WHO pulse surveys
- Alliance-wide engagement on addressing vaccine hesitancy and misinformation
- Epidemic response

Board meeting
24–25 June 2020
WHO survey: immunisation services most at risk of disruption

Countries’ top 10 most frequently reported service disruptions*

1. Immunisation services (outreach: 73%; facility-based: 63%)
2. Rehabilitation services (69%)
3. Dental services (69%)
4. Malaria prevention campaigns (ITN: 68%; SMC: 65%, IRS: 62%)
5. NCD diagnosis and treatment (65%)
6. Family planning and contraception (62%)
7. Treatment for mental health disorders (62%)
8. Cancer diagnosis and treatment (61%)
9. Antenatal care (60%)
10. Sick child services (60%)


Board meeting
24–25 June 2020
Building confidence in vaccines during a pandemic

- Sabin-Aspen report (June 2020): "most powerful way to increase vaccination is through provider recommendations"

- No one size fits all; challenges are locally contextualised and specific, requiring holistic approach

- What we’re doing:
  - working as an Alliance to provide support – Demand Hub
  - stepping up collaboration with civil society
  - taking action with technology platforms
  - connecting countries with locally relevant, practical tools to address vaccination hesitancy and empower health workers
  - developing strategy to address “infodemic” of misinformation
• **COVID-19 highlights need for strong demand generation systems** to build vaccine confidence and community resilience

• Economic fallout of pandemic exacerbates **socio-economic and gender disparities** due to conflict, fragility, migration and urbanisation

• **Communities and civil society organisations** hold key to engaging with immunisation

---

**Generating Evidence**

**Advocating Strategically**

**Building Capacity**

**Transformative Interventions**

**Building Partnerships**

---

**Board meeting**

24–25 June 2020
Exponential growth of Gavi’s digital footprint

- Fresh content daily on #VaccinesWork platform yielded 1 million total page views since mid-March
- 1.74 million impressions of Gavi Tweets from 1–5 June
- #VaccinesWork and #GVS2020 were top trending hashtags on Twitter in Switzerland
- Top mentions using #GVS2020: PM Jakobsdóttir, PM Johnson, PM Macron, PM Modi, Minister Tadesse, Taoiseach Varadkar, Dr Tedros and Melinda Gates
- >3 million video views on Facebook in first week of June
- COVID-19 page on Gavi.org with articles, dashboard, key news, reprogramming totals, sitreps, partner links

Board meeting
24–25 June 2020
Enabling fair and equitable access to COVID-19 vaccines

Access to COVID-19 Tools (ACT) Accelerator structure and Vaccines Pillar

**Vaccines Pillar**
- Development, scale-up and delivery of COVID-19 vaccines

**Diagnostics Pillar**
- Innovation and global access to diagnostics

**Therapeutics Pillar**
- Evidence and adoption of therapeutics for prophylaxis and treatment

**CEPI**
- World Health Organization
- Gavi

Vaccines Pillar
- Vaccine Development and Manufacturing
- Vaccine Allocation and Policy
- Vaccine Procurement and Delivery-at-Scale

COVAX Facility

Board meeting
24–25 June 2020
COVID-19 Global Vaccine Access Facility

Primary objective
Accelerate global equitable access of appropriate, safe and efficacious vaccines

Supporting objectives
• **Secure supply rapidly** through at risk scale-up of manufacturing
• **Reduce demand uncertainty and predictability** as a barrier to manufacturing scale-up
• Have an **actively managed portfolio** of vaccines to use facilities and supplies most efficiently

Benefits to all countries
• Access to a large portfolio of affordable COVID-19 vaccines
• Higher global coverage → protection against cross-border transmission → economic recovery

Benefits to lower-income countries
• Financing support for LICs/LMICs for vaccine procurement, delivery and technical assistance
Gavi Advance Market Commitment for COVID-19 Vaccines (Gavi COVAX AMC)

- Part of new COVAX Facility – the Gavi COVAX AMC is the official development assistance (ODA)-supported financing instrument of the COVAX Facility
- ODA support to high-risk populations in lower-income countries (LICs/LMICs)
- Investment opportunity of US$ 2 billion as seed funding
- Incentivise manufacturers through guarantees to ensure sufficient global capacity before vaccines are licensed
- LICs/LMICs get access to vaccines as soon as they become available
- Doses allocated per WHO’s Global Allocation Framework

Board meeting
24-25 June 2020
Reporting back on previous Board decisions
2019: Continued ramp-up in scale of programme and support to countries

- 59 vaccine introductions – exceeded target of 56
- A record US$ 331 million in HSS disbursements
  - Growth since 2009 and increasingly targeted to immunisation bottlenecks
- CCEOP: 20,000 units procured (target met)
  - US$ 10.5 million savings achieved
  - Significant achievements gained in market health
- Co-financing performance reached an all-time high
  - Timely fulfillment of obligations by 49 of 50 countries; only 1 defaulting country
Successful conclusion of Pneumococcal AMC pilot

• 10-year pilot Advance Market Commitment (AMC) for pneumococcal vaccines ends as planned in December 2020

• Estimated 225 million* children across 60 countries protected against leading cause of pneumonia

• Third supplier to AMC makes PCV available at US$ 2.00 per dose (43% reduction from Gavi price at AMC start)

* Projected data. Actual 2019 data will become available in July/August 2020. From programme start through end 2018, more than 183 million children were immunised with AMC-supported pneumococcal vaccines. Coverage for pneumococcal vaccines in low-income countries is higher than the global average.
Digital immunisation platform helps Sindh, Pakistan, respond during pandemic

- In Pakistan, informal urban settlements were first to feel COVID-19 impact

- In Sindh province, the Gavi-supported *Zindagi Mehfooz* (“Safe Life”) digital immunisation registry helps >2,400 registered vaccinators protect 2.9 million children

- Missed appointments logged to enable geographic targeting of catch-up programmes

- App trains health workers to prevent COVID-19 transmission
Measles: “tracer” for under-served communities

Number of reported measles cases (6-month period)

<table>
<thead>
<tr>
<th>Country</th>
<th>Cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>DR Congo</td>
<td>19,166</td>
</tr>
<tr>
<td>Nigeria</td>
<td>6,371</td>
</tr>
<tr>
<td>Brazil</td>
<td>6,069</td>
</tr>
<tr>
<td>Kazakhstan</td>
<td>4,755</td>
</tr>
<tr>
<td>India</td>
<td>4,516</td>
</tr>
<tr>
<td>Uzbekistan</td>
<td>4,508</td>
</tr>
<tr>
<td>Philippines</td>
<td>4,424</td>
</tr>
<tr>
<td>Central African Republic</td>
<td>4,194</td>
</tr>
<tr>
<td>Bangladesh</td>
<td>3,627</td>
</tr>
<tr>
<td>Ethiopia</td>
<td>2,434</td>
</tr>
</tbody>
</table>

Because measles is highly infectious, its presence serves as a tracer (the “canary in the coal mine”) of inadequate coverage and gaps in the health system.

–Immunisation Agenda 2030: A global strategy to leave no one behind

* Dr. Katherine O’Brien, Director of WHO Immunization, Vaccines and Biologicals Department, report to SAGE (31 March 2020)

Board meeting
24–25 June 2020
COVID-19: drops in measles-rubella routine coverage, suspension of preventive campaigns

Bangladesh case study

- Ministry of Health released guidelines for conducting immunisation in the context of COVID-19
- Training of 26,000 frontline health care workers on infection prevention and control, communication strategies (by end June 2020)
- Ongoing discussions on resumption of modified MR preventive campaign and opportunities for integration

Board meeting
24–25 June 2020
“Measles deaths will rebound if immunisation programmes fail”*

*Dr. Katherine O’Brien, Director of WHO Immunization, Vaccines and Biologicals Department, report to SAGE (31 March 2020)
Impact of COVID-19 on polio: ensuring hard-won gains not lost

- GPEI paused polio vaccination activities; AFP and environmental surveillance continued

- Ongoing outbreaks in 16 countries: marked increase over 2019 case numbers

- Risks in maintaining status quo; opportunity for new strategies coming out of lockdowns

- Mitigating impact of COVID-19

- Implications for GPEI’s Endgame Strategy, timelines and budget

YEAR-TO-DATE 2020
Jan 1 – Jun 17, 2020
64 WPV 135 cVDPV

YEAR-TO-DATE 2019
Jan 1 – Jun 17, 2019
51 WPV 47 cVDPV

Credit: UNICEF/Chad
Outbreaks in the context of COVID-19: 2020

Cholera outbreaks
• Bangladesh, Cameroon, DRC, Ethiopia, Mozambique, Uganda
  • In 2020, 3.4 million OCV doses shipped to Bangladesh, Cameroon, DRC, Mozambique and Uganda for emergency response
  • In 2020, 1.9 million OCV doses shipped to Bangladesh and Malawi for preventive hotspot vaccination

Diphtheria outbreak
• Yemen

Ebola outbreak
• Democratic Republic of the Congo (DRC)
  • 11th outbreak since records began; new cases in Équateur Province
  • As of 13 June 2020, >2,500 people vaccinated with ERVEBO® (Merck) vaccine in Équateur Province
  • To date, >308,000 people in DRC reached with Gavi-funded vaccines

Measles outbreaks
• Angola, Bangladesh, Brazil, Burkina Faso, Burundi, Cameroon, Central African Republic, Chad, DRC, Ethiopia, Kenya, Nigeria, Tajikistan, Uzbekistan
  • Measles & Rubella Initiative Outbreak Response Fund supported ~800,000 doses for Chad

Yellow fever outbreaks
• Ethiopia, South Sudan, Uganda
  • In 2020, Gavi-funded stockpile doses shipped to Ethiopia (~790,000) and Uganda (>1.8 million)
Impact of COVID-19 on Malaria Vaccine Implementation Programme (MVIP)

Vaccination programmes continue in Malawi, Ghana, Kenya
- COVID-19 mitigation measures being applied

Known impact of COVID-19
- Delays in conducting New Vaccine Post-Introduction Evaluation (PIE) in 3 countries (originally set to be completed by Q2 2020); no new dates

Potential impact of COVID-19
- Delays in conducting 2nd household surveys (originally set to be completed in 2 countries by Q3 2020)
- Timelines for data collection and readiness for policy review (at the earliest in Q1 2022) currently maintained

Too early to assess net budgetary impact

Board meeting
24–25 June 2020
RTS,S update: progress on third-party de-risk for malaria bulk antigen manufacturing

- December 2019: Board asked Secretariat to identify partner(s) and develop a risk-share for continued RTS,S bulk antigen manufacture pending WHO policy and Gavi investment decisions
  - Secretariat in discussion with MedAccess alongside WHO, GSK, PATH
  - Impact of COVID-19 on all organisations has shifted timelines
    - GSK agreed to extended deadline to enable due diligence and negotiations
- MSDC meeting expected Q3/4 2020 depending on progress
Strengthening yellow fever (YF) diagnostic capacity in Africa: an update

- 20 out of 24 eligible countries approved for YF diagnostic support; 1 application under IRC review
- UNICEF Supply Division (SD) secured reagents and equipment for current first-line YF test protocol, despite COVID-19 challenges
- Outreach of manufacturers to submit expressions of interest for test kit validation review; commercialisation of test kits underway
- Progress on fit-for-purpose lab data: guiding vaccination programme decision-making on RI introduction, preventive campaigns and outbreak responses
Ensuring immunisation gains in fragile countries: Yemen, Syria

**Yemen**
- Seminal Alliance mission (Feb. 2020) to Sanaa, Aden
- Immunisation programme strongly supported by North, South authorities
- Agreement on an EPI review in 2020 to inform longer-term strategy, prioritisation and planning

**Syria**
- Partnership Framework Agreement signed (May 2020)
Preparing for transition: Gavi 4.0 to Gavi 5.0

- Reviewing workstreams to deliver effectively against mandate (e.g., cross-Secretariat oversight of “Innovation”)
- Gavi 4.0 spend
  - prior to COVID-19 disruptions, total expenditures were on track (at ~80% of forecast)
  - closely monitoring COVID-19 implications; will be reflected in upcoming forecasts
- Moving goalposts to reflect COVID-19 reality
  - Gavi 5.0 operationalisation
  - Gavi 5.0 M&E framework targets

Organisational review

- Secretariat leadership team workshops in Q1; COVID-19 triggered pause
- Plan to restart in Q3
- Need to factor in COVID-19 impact on programmes and additional activities (e.g., Gavi COVAX AMC)

Board meeting
24–25 June 2020
Alliance and Secretariat update
Resilience of Secretariat in lockdown

Robust IT solutions enabled seamless, uninterrupted collaboration

• Rapid transition to a virtual donor pledging conference
• Continued engagement of stakeholders across the globe despite travel ban

Proactive and vigilant human resources and operations planning

• DC and Geneva office reopened on 15 June for up to 20% staff, based on needs (ie, printing) but default still work at home
• Few COVID-19 cases among staff; all recovered

Keeping staff connected

• News bulletins, wellness programme, frequent virtual all-staff meetings, staff pulse surveys, morning radio show, Gavi@Home group to share stories of home working, intranet
Gavi Secretariat update

New senior hires

Hannah Burris
Chief of Staff

Olly Cann
Director
Communications

Brenda Killen
Director
Governance

Derrick Sim
Director
Vaccine Supply & Demand

Board meeting
24–25 June 2020
With gratitude to Phil Armstrong ....

For his leadership and dedicated service to Gavi’s governance from August 2015 through September 2020

Board meeting
24–25 June 2020
THANK YOU

Credit: Gavi/Isaac Gliberg